Novartis Historical Income Statement

NVS Stock  USD 95.88  0.61  0.64%   
Historical analysis of Novartis income statement accounts such as Selling And Marketing Expenses of 12.8 B can show how well Novartis AG ADR performed in making a profits. Evaluating Novartis income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Novartis's future profits or losses.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Novartis AG ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novartis AG ADR is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

About Novartis Income Statement Analysis

Novartis AG ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Novartis shareholders. The income statement also shows Novartis investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Novartis Income Statement Chart

Novartis AG ADR Income Statement is one of the three primary financial statements used for reporting Novartis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Novartis AG ADR revenue and expense. Novartis Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Novartis' Net Income From Continuing Ops is comparatively stable compared to the past year. Tax Provision is likely to gain to about 1.7 B in 2024, whereas Interest Expense is likely to drop slightly above 550.6 M in 2024.

Total Revenue

Total revenue comprises all receipts Novartis AG ADR generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Novartis AG ADR minus its cost of goods sold. It is profit before Novartis operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.
Most accounts from Novartis' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
At this time, Novartis' Net Income From Continuing Ops is comparatively stable compared to the past year. Tax Provision is likely to gain to about 1.7 B in 2024, whereas Interest Expense is likely to drop slightly above 550.6 M in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit37.0B36.3B34.2B32.3B
Total Revenue52.9B51.8B46.7B46.2B

Novartis income statement Correlations

0.930.550.710.580.640.590.190.240.880.520.40.690.190.020.31-0.02-0.070.3-0.050.340.04-0.51-0.040.43
0.930.490.80.780.810.790.290.40.90.630.630.850.350.190.320.160.150.140.080.340.09-0.44-0.160.21
0.550.490.230.040.170.030.280.350.320.48-0.20.20.360.030.29-0.04-0.530.410.320.70.25-0.54-0.020.56
0.710.80.230.890.930.860.290.310.910.490.70.930.26-0.020.26-0.020.320.030.020.090.01-0.090.110.26
0.580.780.040.890.980.990.350.420.830.540.930.980.370.130.280.230.52-0.070.11-0.010.090.02-0.14-0.11
0.640.810.170.930.980.950.420.450.880.590.830.980.40.020.320.230.410.010.140.10.140.02-0.110.01
0.590.790.030.860.990.950.270.360.820.490.950.970.30.20.230.190.54-0.080.04-0.050.02-0.04-0.11-0.12
0.190.290.280.290.350.420.270.940.320.880.20.30.94-0.260.760.51-0.190.150.890.570.950.01-0.47-0.11
0.240.40.350.310.420.450.360.940.340.950.310.371.00.080.780.45-0.130.010.940.510.89-0.13-0.46-0.07
0.880.90.320.910.830.880.820.320.340.570.650.890.28-0.040.38-0.010.140.20.010.160.08-0.230.070.32
0.520.630.480.490.540.590.490.880.950.570.40.540.930.080.780.39-0.130.10.810.550.79-0.27-0.420.07
0.40.63-0.20.70.930.830.950.20.310.650.40.860.260.310.190.210.66-0.20.03-0.2-0.010.01-0.18-0.32
0.690.850.20.930.980.980.970.30.370.890.540.860.310.10.250.170.420.010.050.060.04-0.08-0.050.03
0.190.350.360.260.370.40.30.941.00.280.930.260.310.060.760.48-0.140.010.950.540.9-0.1-0.48-0.1
0.020.190.03-0.020.130.020.2-0.260.08-0.040.080.310.10.06-0.01-0.090.33-0.440.06-0.3-0.25-0.220.0-0.04
0.310.320.290.260.280.320.230.760.780.380.780.190.250.76-0.010.1-0.230.490.720.340.750.0-0.220.16
-0.020.16-0.04-0.020.230.230.190.510.45-0.010.390.210.170.48-0.090.10.36-0.210.40.320.460.24-0.79-0.69
-0.070.15-0.530.320.520.410.54-0.19-0.130.14-0.130.660.42-0.140.33-0.230.36-0.42-0.27-0.48-0.340.43-0.22-0.6
0.30.140.410.03-0.070.01-0.080.150.010.20.1-0.20.010.01-0.440.49-0.21-0.42-0.020.370.16-0.030.060.31
-0.050.080.320.020.110.140.040.890.940.010.810.030.050.950.060.720.4-0.27-0.020.50.92-0.06-0.43-0.07
0.340.340.70.09-0.010.1-0.050.570.510.160.55-0.20.060.54-0.30.340.32-0.480.370.50.57-0.5-0.380.09
0.040.090.250.010.090.140.020.950.890.080.79-0.010.040.9-0.250.750.46-0.340.160.920.57-0.05-0.47-0.12
-0.51-0.44-0.54-0.090.020.02-0.040.01-0.13-0.23-0.270.01-0.08-0.1-0.220.00.240.43-0.03-0.06-0.5-0.05-0.02-0.33
-0.04-0.16-0.020.11-0.14-0.11-0.11-0.47-0.460.07-0.42-0.18-0.05-0.480.0-0.22-0.79-0.220.06-0.43-0.38-0.47-0.020.55
0.430.210.560.26-0.110.01-0.12-0.11-0.070.320.07-0.320.03-0.1-0.040.16-0.69-0.60.31-0.070.09-0.12-0.330.55
Click cells to compare fundamentals

Novartis Account Relationship Matchups

Novartis income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization6.5B7.1B6.1B7.2B8.3B4.3B
Interest Expense850M869M811M837M855M550.6M
Selling General Administrative14.4B14.2B14.8B14.3B14.3B15.0B
Total Revenue48.7B49.9B52.9B51.8B46.7B46.2B
Gross Profit34.3B34.8B37.0B36.3B34.2B32.3B
Other Operating Expenses39.6B39.7B41.2B42.6B36.9B36.9B
Operating Income9.1B10.2B26.9B9.2B9.8B9.9B
Ebit9.1B10.2B26.9B9.2B10.2B10.5B
Research Development9.4B9.0B9.5B10.0B11.4B7.8B
Ebitda15.6B17.2B33.1B16.4B18.5B14.8B
Cost Of Revenue14.4B15.1B15.9B15.5B12.5B13.9B
Total Operating Expenses25.2B24.6B25.3B27.1B24.4B23.0B
Income Before Tax8.9B9.9B26.1B8.4B9.1B10.2B
Total Other Income Expense Net(146M)(274M)(811M)(826M)(227M)(215.7M)
Net Income7.1B8.1B24.0B7.0B14.9B9.7B
Income Tax Expense1.8B1.8B2.1B1.4B551M523.5M
Net Income Applicable To Common Shares11.7B8.1B24.0B7.0B8.0B9.8B
Minority Interest77M68M3M2M(4M)(3.8M)
Net Income From Continuing Ops7.1B8.1B24.0B7.0B8.2B10.8B
Tax Provision1.8B1.8B2.1B1.4B1.4B1.7B
Interest Income36M91M14.6B379M627M595.7M
Net Interest Income(645M)(947M)(891M)(633M)(492M)(516.6M)
Reconciled Depreciation5.8B6.5B6.1B7.2B9.0B7.5B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.987
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
22.467
Quarterly Revenue Growth
0.074
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.